

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 November 2006 (09.11.2006)

PCT

(10) International Publication Number
WO 2006/117240 A3

(51) International Patent Classification:
C07K 14/35 (2006.01) **A61K 39/04** (2006.01)

(74) Agent: **TEUTEN, Andrew, J.**; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(21) International Application Number:
PCT/EP2006/004319

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 27 April 2006 (27.04.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/676,549 29 April 2005 (29.04.2005) US
60/777,017 27 February 2006 (27.02.2006) US

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*): **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; Rue de L'Institut 89, B-1330 Rixensart (BE). **INFECTIOUS DISEASE RESEARCH INSTITUTE (IDRI)** [US/US]; 1124 Columbia Street, Suite 600, Seattle, Washington 98104 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **COLER, Rhea** [TT/US]; Infectious Disease Research Institute (IDRI), 1124 Columbia Street, Suite 600, Seattle, Washington 98104 (US). **LOBET, Yves** [BE/BE]; GlaxoSmithKline Biologicals s.a., Rue de L'Institut 89, B-1330 Rixensart (BE). **REED, Steven** [US/US]; Infectious Disease Research Institute (IDRI), 1124 Columbia Street, Suite 600, Seattle, Washington 98104 (US).

Published:

— with international search report

(88) Date of publication of the international search report:
18 January 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL METHOD FOR PREVENTING OR TREATING M TUBERCULOSIS INFECTION

(57) Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.



WO 2006/117240 A3